Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (March 2017)

24 slides from Zydus Lifesciences's investor presentation, Mar 22, 2017

  1. Slide 1: Covering letter to stock exchanges: Updated Investors' Presentation

    Zydus Cadila Healthcare Limited * dedicated/f to ife Regd. Office : Zydus Tower’ Satellite Cross Roads, Ahmedabad 380 015. India. Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2368 www.zyduscadila.com CIN:L24230GJ1995PLC025878 BSE Limited 1° Floor, P.J. Towers Dalal Street Mumbai — 400 001 K

  2. Slide 2: Cadila Healthcare Limited Investor Presentation March 2017

    Cadila Healthcare Limited Investor Presentation March 2017

  3. Slide 3: A Leading Pharmaceutical Company

    A Leading Pharmaceutical Company Leading pharmaceutical company in India 1 With a Global Footprint #4 Market share of 4.2% Revenue Split for 9MFY17 5 Animal Health Others 5% 5% US Generics player (based on scripts) 2 #10 Wellness Market share of 3.2% 5% EU US Formulations Formulations 3% 39% 198 AND

  4. Slide 4: Vertically Integrated Business Model with Presence Across The Pharma Value Chain

    Vertically Integrated Business Model with Presence Across The Pharma Value Chain Generics and Specialty and Biologics and APIs Niche Branded NCEs Vaccines Generics Business  Selective backward  Increased focus on  Focus on pain  Biologics: 25 in pipeline  NCEs: 5 in the pipeline integration nic

  5. Slide 5: Key Business Segments

    Key Business Segments Key Formulations Businesses Other Businesses & Emerging Businesses Alliances Divisions  India formulations  EU Formulations  Biologics  #4 by value  Consumer Wellness  Vaccines  4.2% market share  Animal Health  NCEs  US formulations  APIs  #10 by prescription volum

  6. Slide 6: Track Record of Value Creation

    Track Record of Value Creation US$ MM 2 CAGR: 21% 1500 1,469 Total Income 1000 691 from Operations 500 221 0 FY06 FY11 FY16 US$ MM 2 CAGR: 26% 300 227 200 Net Profit 106 100 22 0 FY06 FY11 FY16 US$ MM 2 CAGR: 23% 8000 6,780 6000 Current Market Market Capitalization 3 4000 2,413 Capitalisation 1 4,84

  7. Slide 7: Key Business Segments

    Zydus rm life Key Business Segments

  8. Slide 8: US Generics: Strong Platform with Robust Growth

    US Generics: Strong Platform with Robust Growth Our US Formulations Business US Generics Growing at CAGR of ~30% Gross Sales, US$ MM  #10 generics player in US (based on scripts) with a market share of 3.2% 800  Among top 3 for more than 70% of the products marketed in US 614  Sale of generic ora

  9. Slide 9: Strong Filing Track Record and Addition to Capabilities

    Strong Filing Track Record and Addition to Capabilities Growing Focus on Complex Generics Business  Modified Release Oral Solids  Immediate Release Oral Solids  Transdermals  Injectables  Topicals  Controlled Substances  Nasal Sprays Track Record of ANDA Filings # (filings annually) Total AND

  10. Slide 10: Large ANDA Pipeline With Increasing Focus on Niche Filings

    Large ANDA Pipeline With Increasing Focus on Niche Filings Approved ANDAs by Type ANDA Pending Approval—Focus on Niche Segments As on 31 Dec 2016 As on 31 Dec 2016 Total Approved ANDAs—1071 Total ANDAs Pending Approval—198; market size of +$75 Bn2 Transdermal Topicals Patches Nasal Injectables 18 3

  11. Slide 11: Strong Leadership in India Formulations Business

    Strong Leadership in India Formulations Business Leading Player in the $16 Bn Market of India India Formulation Sales: Strong Base with Steady Growth US$ MM 2 #4 Leading pharmaceutical company in India 1 8.6% 11.1% 500 444 4.2% Domestic market share 1 400 400 368 359 17 Brands among top 300 in India

  12. Slide 12: Focus on Key Therapeutic Areas in India

    Focus on Key Therapeutic Areas in India Key Therapeutics Areas for Zydus As per AWACS MAT December 2016 Anti-Infective Leadership positions in Women’s Health, Dermatology, 15.1% CVS, Pain Management, Respiratory and GI Others 22.1% Brand acquisitions to fill the portfolio gaps – recently acquired br

  13. Slide 13: Other Growing Formulations Markets

    Other Growing Formulations Markets Latin America Emerging Markets Emerging Markets in Asia and Africa Market Size1 US$ 27 Bn US$ 8 Bn Market Size1 US$ 13 Bn Market Growth ~14% (7%) Market Growth ~12-13% Zydus Size2 US$ 36 MM Zydus Size2 US$ 74 MM Zydus Growth ~10% Zydus Growth ~11%  Branded generic

  14. Slide 14: Other Businesses

    Other Businesses Europe Formulations Consumer Wellness  Operates through Zydus Wellness, listed in India  Brand extensions and new product launches Market Size1 ~US$ 5.7 Bn  Geographical expansion  ~US$ 68 MM revenues Market Growth ~4% Zydus Size2 US$ 40 MM  Among top 10 in France, among top 20

  15. Slide 15: Successful Track Record of Global Partnerships

    Successful Track Record of Global Partnerships Value Creation Through Win-win Alliances and Be a Partner of Choice Zydus Takeda JV Zydus Hospira JV  50:50 JV with Takeda Pharmaceuticals  50:50 contract manufacturing JV with Hospira1 for oncology injectable products  State-of-the-art manufacturing

  16. Slide 16: Manufacturing and Innovation

    Manufacturing and Innovation

  17. Slide 17: Strong Base of Cost Efficient and High Quality Manufacturing Facilities

    Strong Base of Cost Efficient and High Quality Manufacturing Facilities 30 11 +15 Bn Facilities across Facilities Annual capacity India, US, Brazil inspected by of pills and Germany USFDA 16 facilities for formulations, 4 for API, 3 for vaccines, 3 for biologics, 2 for consumer wellness and 2 for an

  18. Slide 18: Key Focus Areas for R&D

    Key Focus Areas for R&D R&D expenditure formed ~7.5% 1 of operating revenues Generics Development  650+ dedicated scientists  Increasing focus on  complex dosage forms like transdermals, topicals and nasals  specialty products and 505(b)(2) route  331 US ANDAs filed (incl. 26 for partners), 120

  19. Slide 19: Capabilities in Complex Segments

    Capabilities in Complex Segments Biologics Vaccines NCEs  Launched 8 products in India and 2 in  Launched 3 products, received  Launched Lipaglyn® – 1st NCE launched Emerging Market geographies marketing authorizations for 6 other by an Indian company for 2 indications (Dyslipidemia and Hypertrig

  20. Slide 20: Key Financials

    Zydus rm life Key Financials

  21. Slide 21: Strong Financial Profile

    Strong Financial Profile Consolidated Revenues 2 EBITDA and PAT Margins 2 US$ MM % 2000 19.8% 13.7% 30% 24.2% 1600 1468 20.3% 20.3% 1291 1078 1060 20% 16.6% 1200 800 15.5% 10% 13.3% 13.7% 400 11.1% 0 0% FY14 FY15 FY16 9M FY17 FY14 FY15 FY16 9M FY17 YoY Growth EBITDA margins PAT margins 2 Return Rati

  22. Slide 22: Strategies For The Future

    Strategies For The Future 1 Strong execution focus for the US market; drive growth with continuous focus on product launches 2 Focus on difficult to develop and manufacture and specialty products to improve margins In India, focus on high growth Therapeutic Areas, in-licensing, outperform the domest

  23. Slide 23: Building Blocks For Our Strategy

    Building Blocks For Our Strategy • Focus on best in class manufacturing Regulatory Compliance • People training and Quality • QUEST: Quality Excellence by Sustainable Transformation; Institutionalising a Culture of Quality Operational • PRISM – cost optimization program adopted in 2002 and instituti

  24. Slide 24: Thank You

    Thank You DISCLAIMER AND SAFE HARBOUR STATEMENT THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general backgroun

Cadila Healthcare — Investor Presentation (March 2017) on 6ix